CELADON PHARMACEUTICALS PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 102.5 GBX | -2.38% |
|
-10.87% | -10.87% |
Valuation
| Fiscal Period: December | 2022 |
|---|---|
| Capitalization 1 | 31.14 |
| Enterprise Value (EV) 1 | 30.71 |
| P/E ratio | -1.71 x |
| Yield | - |
| Capitalization / Revenue | 1,297,634,792 x |
| EV / Revenue | 1,279,759,792 x |
| EV / EBITDA | -2,439,768 x |
| EV / FCF | -5,383,622 x |
| FCF Yield | -0% |
| Price to Book | 4.06 x |
| Nbr of stocks (in thousands) | 61,670 |
| Reference price 2 | 0.5050 |
| Announcement Date | 6/5/23 |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Net sales | - | - | - | 0.024 |
| EBITDA | - | -0.6602 | - | -12.59 |
| EBIT 1 | -0.0475 | -0.1402 | -0.3945 | -12.92 |
| Operating Margin | - | - | - | -53,820.83% |
| Earnings before Tax (EBT) 1 | -0.1517 | -0.1745 | -0.2193 | -18.12 |
| Net income 1 | -0.1517 | -0.1745 | -0.2193 | -17.01 |
| Net margin | - | - | - | -70,858.33% |
| EPS | - | -0.0285 | -0.0292 | -0.2951 |
| Free Cash Flow | - | -0.885 | -2.22 | -5.705 |
| FCF margin | - | - | - | -23,771.35% |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 2/28/22 | 4/28/22 | 4/28/22 | 6/5/23 |
1GBP in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Net Debt 1 | 2.53 | - | - | - |
| Net Cash position 1 | - | 5.49 | 4.46 | 0.43 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | -0.89 | -2.22 | -5.71 |
| ROE (net income / shareholders' equity) | - | 14,681% | -6.74% | -1,319% |
| ROA (Net income/ Total Assets) | - | -14.2% | -4.72% | -73.3% |
| Assets 1 | - | 1.228 | 4.651 | 23.19 |
| Book Value Per Share | - | 0.8900 | 0.8000 | 0.1200 |
| Cash Flow per Share | - | 0.9000 | 0.5600 | 0.0800 |
| Capex | - | 0.71 | -0.29 | 2.09 |
| Capex / Sales | - | - | - | 8,691.67% |
| Announcement Date | 2/28/22 | 4/28/22 | 4/28/22 | 6/5/23 |
1GBP in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.025
GBP
Average target price
2.35
GBP
Spread / Average Target
+129.27%
| 1st Jan change | Capi. | |
|---|---|---|
| -10.87% | 81.98M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- CEL Stock
- Financials Celadon Pharmaceuticals Plc
